At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 109 enrolled
Drug / intervention
Vandetanib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer in Patients Who Have Failed Therapy With an Irinotecan and Fluoropyrimidine Regimen
In Brief
A Phase 2 clinical trial evaluating Vandetanib and FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid for Colorectal and Cancer. Completed, enrolled 109 participants across 15 sites in 6 countries.
Detailed Summary
The purpose of this study is to determine whether treatment with ZACTIMA (vandetanib) in combination with FOLFOX is more effective than FOLFOX alone for colorectal cancer in patients who have failed therapy with an irinotecan and fluoropyrimidine containing regimen.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal, Cancer
CountriesFrance, Hungary, Slovakia, South Korea, Spain, Taiwan
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedJul 2007
Primary CompletionMar 2008
Study CompletionNov 2016
TodayJul 2026
First PostedJul 12, 2007
Enrollment StartMar 1, 2007
Primary CompletionMar 1, 2008
Study CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 19.0 years ago
Interventions
Vandetanibdrug
once daily oral tablet two dose strengths
FOLFOX regimen=oxaliplatin, fluorouracil, & folinic aciddrug
intravenous infusion